Glyset en es it fr

Glyset Brand names, Glyset Analogs

Glyset Brand Names Mixture

  • No information avaliable

Glyset Chemical_Formula


Glyset RX_link

No information avaliable

Glyset fda sheet

Glyset msds (material safety sheet)

Glyset Synthesis Reference

No information avaliable

Glyset Molecular Weight

427.518 g/mol

Glyset Melting Point

156-157 oC

Glyset H2O Solubility

0.457 mg/L

Glyset State


Glyset LogP


Glyset Dosage Forms

Film-coated tablets (200-mg, 250-mg, or 300-mg)

Glyset Indication

Used to treat irregular heartbeats (arrhythmias) and maintain a normal heart rate.

Glyset Pharmacology

Moricizine is used to treat irregular heartbeats (arrhythmias) and to maintain a normal heart rate. It acts on the heart muscle to improve the heart's rhythm. Moricizine has potent local anesthetic activity and membrane stabilizing effect. Decreases excitability, conduction velocity, and automaticity as a result of slowed atrioventricular (AV) nodal and His-Purkinje conduction. Decreases the action potential duration (APD) in Purkinje fibers; also decreases the effective refractory period (ERP) but to a lesser extent than the APD, so the ERP/APD ratio is increased. Decreases the maxiumum rate of Phase 0 depolarization (V max ), but does not affect action potential amplitude or maximum diastolic potential. Does not affect atrial, AV nodal, or left ventricular refractory periods and has minimal effect on ventricular repolarization (evidenced by the overall decrease in JT interval). Has no effect on sinoatrial (SA) nodal or intra-atrial conduction and only minimal effect on sinus cycle length and sinus node recovery time. In the Vaughan Williams classification of antiarrhythmics, moricizine is considered to be a class I agent. It has properties of class IA, IB, and IC agents but does not clearly belong to any of the three subclasses. It has less effect on the slope of phase 0 and a greater effect on action potential duration and effective refractory period than class IC agents.

Glyset Absorption

Well absorbed, absorption is complete within 2 to 3 hours. Significant first-pass metabolism results in an absolute bioavailability of approximately 38%. Administration within 30 minutes after a meal slows the rate, but does not affect the extent of absorption, although peak plasma concentrations are reduced.

Glyset side effects and Toxicity

Symptoms of overdose include vomiting, unconsciousness, and severe low blood pressure.

Glyset Patient Information

Glyset Organisms Affected

Humans and other mammals